The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
Adenylyl Cyclases
Animals
Caspase 1
/ metabolism
Diabetes Mellitus, Experimental
/ metabolism
Diabetic Retinopathy
/ metabolism
Endoplasmic Reticulum Stress
/ drug effects
Inflammasomes
/ metabolism
Interleukin-18
/ metabolism
Interleukin-1beta
/ metabolism
Mice
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Receptors, G-Protein-Coupled
/ metabolism
Retina
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
11
2018
accepted:
04
01
2019
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
23
10
2019
Statut:
epublish
Résumé
The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA2 receptors exert an anti-inflammatory effect on the retinal damage induced by diabetes when activated by the endogenous ligand β-hydroxybutyrate. Seven-to-10-week-old C57BL6J mice were rendered diabetic by a single intraperitoneal injection of streptozotocin (75 mg/kg of body weight) and monitored intermittently over a 10-week period extending from the initial diabetes assessment. Mice with a fasting blood glucose level higher than 250 mg/dl for 2 consecutive weeks after streptozotocin injection were treated twice a week with intraperitoneal injections of 25-50-100 mg/kg β-hydroxybutyrate. Interestingly, while the retinal endoplasmic reticulum stress markers (pPERK, pIRE1, ATF-6α) were elevated in diabetic C57BL6J mice, their levels were significantly reduced by the systemic intraperitoneal treatment with 50 mg/kg and 100 mg/kg β-hydroxybutyrate. These mice also exhibited high NLRP3 inflammasome activity and proinflammatory cytokine levels. In fact, the elevated levels of retinal NLRP3 inflammasome activation markers (NLRP3, ASC, caspase-1) and of the relative proinflammatory cytokines (IL-1β, IL-18) were significantly reduced by 50 mg/kg and 100 mg/kg β-hydroxybutyrate treatment. These doses also reduced the high apoptotic cell number exhibited by the diabetic mice in the retinal outer nuclear layer (ONL) and increased the ONL low connexin 43 expression, leading to an improvement in retinal permeability and homeostasis. These data suggest that the systemic treatment of diabetic C57BL6J mice with BHB activates retinal HCA2 and inhibits local damage.
Identifiants
pubmed: 30657794
doi: 10.1371/journal.pone.0211005
pii: PONE-D-18-32944
pmc: PMC6338370
doi:
Substances chimiques
Hcar2 protein, mouse
0
IL1B protein, mouse
0
Inflammasomes
0
Interleukin-18
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nlrp3 protein, mouse
0
Receptors, G-Protein-Coupled
0
Casp1 protein, mouse
EC 3.4.22.36
Caspase 1
EC 3.4.22.36
Adenylyl Cyclases
EC 4.6.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211005Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3758-63
pubmed: 20130277
Mol Vis. 2009;15:362-72
pubmed: 19223991
Invest Ophthalmol Vis Sci. 2014 Jun 17;55(7):4327-37
pubmed: 24938518
Nat Med. 2003 Mar;9(3):352-5
pubmed: 12563315
Front Endocrinol (Lausanne). 2011 Oct 25;2:51
pubmed: 22654812
Cardiovasc Hematol Disord Drug Targets. 2009 Sep;9(3):222-9
pubmed: 19619127
Acta Ophthalmol. 2017 Dec;95(8):803-808
pubmed: 28271611
Annu Rev Pharmacol Toxicol. 2004;44:43-66
pubmed: 14744238
Indian J Med Res. 2016 Oct;144(4):515-524
pubmed: 28256459
J Biol Chem. 2005 Jul 22;280(29):26649-52
pubmed: 15929991
Metabolism. 2016 Feb;65(2):102-13
pubmed: 26773933
Adv Exp Med Biol. 2016;854:73-8
pubmed: 26427396
Front Mol Neurosci. 2018 Mar 20;11:86
pubmed: 29662437
Exp Diabetes Res. 2007;2007:95103
pubmed: 18274606
Biochem Biophys Res Commun. 2003 Mar 28;303(1):364-9
pubmed: 12646212
J Clin Immunol. 2010 Sep;30(5):628-31
pubmed: 20589420
Sci Rep. 2017 Aug 9;7(1):7677
pubmed: 28794421
Cell Rep. 2017 Feb 28;18(9):2077-2087
pubmed: 28249154
Pediatr Res. 2007 Mar;61(3):301-6
pubmed: 17314687
Front Pharmacol. 2015 Nov 05;6:262
pubmed: 26594174
J Clin Invest. 2005 Dec;115(12):3634-40
pubmed: 16322797
Nat Med. 2015 Mar;21(3):263-9
pubmed: 25686106
Oncotarget. 2016 Oct 11;7(41):66444-66454
pubmed: 27661104
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5376-82
pubmed: 14638741
Trends Immunol. 2011 Aug;32(8):373-9
pubmed: 21733753
Biochem Biophys Res Commun. 2007 Jan 5;352(1):97-103
pubmed: 17107662
Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2208-17
pubmed: 22427566
J Invest Dermatol. 2006 Dec;126(12):2637-46
pubmed: 17008871
Hong Kong Med J. 2002 Jun;8(3):172-6
pubmed: 12055361
Nat Immunol. 2012 Mar 19;13(4):333-42
pubmed: 22430786
Nat Med. 2011 Feb;17(2):179-88
pubmed: 21217695
J Leukoc Biol. 2004 Mar;75(3):453-9
pubmed: 14657208
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1400-7
pubmed: 19029021
Jpn J Pharmacol. 2001 Oct;87(2):143-50
pubmed: 11700013
Mol Pharmacol. 2006 Dec;70(6):1844-9
pubmed: 17008386
Eur J Immunol. 2001 Dec;31(12):3714-25
pubmed: 11745392
Ophthalmic Res. 1985;17(3):181-4
pubmed: 4011131
Cell Death Differ. 2008 Jan;15(1):134-42
pubmed: 17932499
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992
pubmed: 27646922
Immunol Res. 2010 Jul;47(1-3):153-61
pubmed: 20082152
Oncotarget. 2017 Dec 14;9(25):17257-17269
pubmed: 29707106
Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5
pubmed: 18722346
Diabetes. 2013 Jan;62(1):194-204
pubmed: 23086037
FASEB J. 2019 Jan;33(1):1062-1073
pubmed: 30085883
Biophys Rep. 2018;4(1):39-49
pubmed: 29577068
Immunol Rev. 2015 May;265(1):53-62
pubmed: 25879283
J Biomed Biotechnol. 2010;2010:190724
pubmed: 20182540
Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):624-32
pubmed: 11254515
J Cell Mol Med. 2017 May;21(5):968-974
pubmed: 27998021
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):978-985
pubmed: 29450537
Front Physiol. 2014 Jul 17;5:260
pubmed: 25101001
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Curr Eye Res. 2014 May;39(5):487-92
pubmed: 24215154
Biochim Biophys Acta. 2013 Dec;1833(12):3460-3470
pubmed: 23850759
J Biol Chem. 2009 Aug 14;284(33):21928-33
pubmed: 19561068
Prog Retin Eye Res. 2001 May;20(3):385-414
pubmed: 11286898
Curr Mol Med. 2010 Dec;10(9):802-23
pubmed: 21091424
J Diabetes Res. 2015;2015:616747
pubmed: 26273672
Cell Physiol Biochem. 2018;48(2):705-717
pubmed: 30025404
N Engl J Med. 2004 Jan 1;350(1):48-58
pubmed: 14702427
Am J Med Sci. 2006 May;331(5):243-51
pubmed: 16702793
Mediators Inflamm. 2016;2016:7368389
pubmed: 26949291
Cell Commun Adhes. 2008 May;15(1):195-206
pubmed: 18649190
Gene. 2013 Nov 1;530(1):151-4
pubmed: 23973727
Sci Rep. 2018 Feb 12;8(1):2847
pubmed: 29434227
EMBO Rep. 2006 Sep;7(9):880-5
pubmed: 16953201